{"id":"daclizumab-infliximab","safety":{"commonSideEffects":[{"rate":null,"effect":"Infections (including serious infections)"},{"rate":null,"effect":"Infusion reactions"},{"rate":null,"effect":"Hepatotoxicity"},{"rate":null,"effect":"Autoimmune hepatitis (daclizumab)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Daclizumab is an IL-2 receptor antagonist that selectively depletes activated T cells, particularly CD25+ cells involved in autoimmune responses. Infliximab is a TNF-alpha inhibitor that blocks a key pro-inflammatory cytokine. Together, they provide dual immunosuppression targeting different pathways of immune activation and inflammation.","oneSentence":"This is a combination of two monoclonal antibodies: daclizumab blocks IL-2 receptor alpha on T cells to reduce immune activation, while infliximab blocks TNF-alpha to suppress inflammatory cytokine signaling.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:40:16.852Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Multiple sclerosis (daclizumab component)"},{"name":"Rheumatoid arthritis and inflammatory bowel disease (infliximab component)"}]},"trialDetails":[{"nctId":"NCT00574470","phase":"PHASE4","title":"Anti Cytokine Combination Therapy With Daclizumab and Infliximab for Treatment of Steroid Refractory Acute GVHD","status":"COMPLETED","sponsor":"University of Iowa","startDate":"2006-01","conditions":"Graft vs Host Disease","enrollment":3},{"nctId":"NCT00304954","phase":"PHASE2","title":"Infliximab, Sirolimus and Daclizumab to Treat Age-Related Macular Degeneration","status":"COMPLETED","sponsor":"National Eye Institute (NEI)","startDate":"2006-02","conditions":"Age-Related Macular Degeneration, Choroidal Neovascularization","enrollment":13},{"nctId":"NCT00132691","phase":"PHASE4","title":"Multicenter Uveitis Steroid Treatment (MUST) Trial","status":"COMPLETED","sponsor":"JHSPH Center for Clinical Trials","startDate":"2005-09","conditions":"Uveitis","enrollment":255},{"nctId":"NCT02694770","phase":"PHASE2","title":"A Study Evaluating the Efficacy and Safety of Neihulizumab vs \"Conventional Treatment\" to Treat Sr-aGvHD","status":"WITHDRAWN","sponsor":"AbGenomics B.V Taiwan Branch","startDate":"2016-07","conditions":"Steroid-refractory aGvHD Subsequent to Allogeneic Hematopoietic Cell Transplantation","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"daclizumab, infliximab","genericName":"daclizumab, infliximab","companyName":"University of Iowa","companyId":"university-of-iowa","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This is a combination of two monoclonal antibodies: daclizumab blocks IL-2 receptor alpha on T cells to reduce immune activation, while infliximab blocks TNF-alpha to suppress inflammatory cytokine signaling. Used for Multiple sclerosis (daclizumab component), Rheumatoid arthritis and inflammatory bowel disease (infliximab component).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}